Pharma Stock Shifts: Upgrades and Downgrades

The hosts introduce a sponsor segment before analyzing recent pharmaceutical upgrades and downgrades. They discuss Gilead's positive outlook and Merck's decline, hinting at the implications for investors.

Transcript

Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app